John A. Zebala

2.6k total citations · 1 hit paper
41 papers, 1.5k citations indexed

About

John A. Zebala is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, John A. Zebala has authored 41 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 17 papers in Molecular Biology and 14 papers in Immunology. Recurrent topics in John A. Zebala's work include Cancer Immunotherapy and Biomarkers (12 papers), Chemokine receptors and signaling (9 papers) and Immune cells in cancer (7 papers). John A. Zebala is often cited by papers focused on Cancer Immunotherapy and Biomarkers (12 papers), Chemokine receptors and signaling (9 papers) and Immune cells in cancer (7 papers). John A. Zebala collaborates with scholars based in United States, Austria and Germany. John A. Zebala's co-authors include Dean Y. Maeda, Francis Barany, Claudia Palena, Lucas A. Horn, Jeffrey Schlom, Ronald A. DePinho, Clint Allen, Yvette Robbins, Paúl E. Clavijo and Sarah Greene and has published in prestigious journals such as Nature, Journal of the American Chemical Society and Nucleic Acids Research.

In The Last Decade

John A. Zebala

40 papers receiving 1.4k citations

Hit Papers

Effective combinatorial immunotherapy for castration-resi... 2017 2026 2020 2023 2017 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Effective combinatorial immunotherapy for castration-resistant prostate cancer
    2017 396 citations John A. Zebala, Dean Y. Maeda et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John A. Zebala United States 14 795 787 457 199 98 41 1.5k
Julie Stockis Belgium 17 589 0.7× 418 0.5× 505 1.1× 71 0.4× 142 1.4× 21 1.3k
Massimo Ammirante United States 12 819 1.0× 828 1.1× 629 1.4× 302 1.5× 284 2.9× 15 1.7k
Veronica C. Ardi United States 14 539 0.7× 542 0.7× 596 1.3× 110 0.6× 336 3.4× 15 1.4k
Donna Butcher United States 19 330 0.4× 276 0.4× 366 0.8× 171 0.9× 120 1.2× 39 956
Lopamudra Das Roy United States 16 369 0.5× 599 0.8× 605 1.3× 52 0.3× 203 2.1× 31 1.1k
Shashank J. Patel United States 10 664 0.8× 608 0.8× 644 1.4× 105 0.5× 169 1.7× 20 1.4k
Douglas Halverson United States 14 208 0.3× 531 0.7× 720 1.6× 256 1.3× 129 1.3× 18 1.2k
Sandra Cristea United States 8 344 0.4× 898 1.1× 906 2.0× 207 1.0× 173 1.8× 9 1.5k
Michal A. Stanczak Switzerland 16 822 1.0× 479 0.6× 754 1.6× 109 0.5× 100 1.0× 24 1.4k
Ruoyu Ma China 8 372 0.5× 360 0.5× 345 0.8× 82 0.4× 130 1.3× 10 809

Countries citing papers authored by John A. Zebala

Since Specialization
Citations

This map shows the geographic impact of John A. Zebala's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John A. Zebala with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John A. Zebala more than expected).

Fields of papers citing papers by John A. Zebala

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John A. Zebala. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John A. Zebala. The network helps show where John A. Zebala may publish in the future.

Co-authorship network of co-authors of John A. Zebala

This figure shows the co-authorship network connecting the top 25 collaborators of John A. Zebala. A scholar is included among the top collaborators of John A. Zebala based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John A. Zebala. John A. Zebala is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Patel, Sapna P., Anastasios Dimou, Adrienne I. Victor, et al.. (2024). Safety and efficacy of first-in-class CXCR1/2 inhibitor SX-682 in combination with pembrolizumab (pem) in patients (pts) with metastatic melanoma (mMEL) with disease progression on anti–PD-1 therapy.. Journal of Clinical Oncology. 42(16_suppl). 9508–9508. 10 indexed citations
2.
Horn, Lucas A., Hanne Lind, Kristen Fousek, et al.. (2024). Inhibition of the chemokine receptors CXCR1 and CXCR2 synergizes with docetaxel for effective tumor control and remodeling of the immune microenvironment of HPV-negative head and neck cancer models. Journal of Experimental & Clinical Cancer Research. 43(1). 318–318. 4 indexed citations
3.
Zebala, John A., et al.. (2023). Regression and Eradication of Triple-Negative Breast Carcinoma in 4T1 Mouse Model by Combination Immunotherapies. Cancers. 15(8). 2366–2366. 9 indexed citations
4.
Sallman, David A., Amy E. DeZern, Arlene A. Gayle, et al.. (2022). Phase 1 Results of the First-in-Class CXCR1/2 Inhibitor SX-682 in Patients with Hypomethylating Agent Failure Myelodysplastic Syndromes. Blood. 140(Supplement 1). 2070–2072. 11 indexed citations
5.
Zebala, John A., Aaron D. Schuler, Stuart J. Kahn, & Dean Y. Maeda. (2020). Desmetramadol Is Identified as a G-Protein Biased µ Opioid Receptor Agonist. Frontiers in Pharmacology. 10. 1680–1680. 12 indexed citations
6.
Greene, Sarah, Yvette Robbins, Wojciech K. Mydlarz, et al.. (2019). Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models. Clinical Cancer Research. 26(6). 1420–1431. 217 indexed citations
7.
Kargl, Julia, Xiaodong Zhu, Huajia Zhang, et al.. (2019). Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC. JCI Insight. 4(24). 127 indexed citations
8.
9.
Sun, Lillian, Paúl E. Clavijo, Yvette Robbins, et al.. (2019). Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. JCI Insight. 4(7). 188 indexed citations
10.
Maeda, Dean Y., Aaron D. Schuler, Mark T. Quinn, et al.. (2015). Boronic acid-containing CXCR1/2 antagonists: Optimization of metabolic stability, in vivo evaluation, and a proposed receptor binding model. Bioorganic & Medicinal Chemistry Letters. 25(11). 2280–2284. 12 indexed citations
11.
12.
Menter, Alan, Christina Cherian, Larry H. Matherly, et al.. (2012). Intestinal Transport of Aminopterin Enantiomers in Dogs and Humans with Psoriasis Is Stereoselective: Evidence for a Mechanism Involving the Proton-Coupled Folate Transporter. Journal of Pharmacology and Experimental Therapeutics. 342(3). 696–708. 15 indexed citations
13.
Ye, Guofeng, Aaron D. Schuler, Yousef Ahmadibeni, et al.. (2009). Synthesis and evaluation of phosphopeptides containing iminodiacetate groups as binding ligands of the Src SH2 domain. Bioorganic Chemistry. 37(4). 133–142. 3 indexed citations
14.
Schuler, Aaron D., et al.. (2009). PhotoMorphs™: A novel light‐activated reagent for controlling gene expression in zebrafish. genesis. 47(11). 736–743. 51 indexed citations
15.
Maeda, Dean Y., Mark T. Quinn, Igor A. Schepetkin, Liliya N. Kirpotina, & John A. Zebala. (2009). Nicotinamide Glycolates Antagonize CXCR2 Activity through an Intracellular Mechanism. Journal of Pharmacology and Experimental Therapeutics. 332(1). 145–152. 9 indexed citations
16.
Vijayanathan, Veena, Angela K. Smith, John A. Zebala, Barton A. Kamen, & Peter D. Cole. (2007). High-performance liquid chromatography separation of aminopterin-polyglutamates within red blood cells of children treated for acute lymphoblastic leukemia. Translational research. 150(6). 367–373. 2 indexed citations
17.
Maeda, Dean Y., Sumit Mahajan, William M. Atkins, & John A. Zebala. (2006). Bivalent inhibitors of glutathione S-transferase: The effect of spacer length on isozyme selectivity. Bioorganic & Medicinal Chemistry Letters. 16(14). 3780–3783. 21 indexed citations
18.
19.
Barany, Francis & John A. Zebala. (1992). Correlation between insertion mutant activities and amino acid sequence identities of the TaqI and TthHB8 restriction endonucleases. Gene. 112(1). 13–20. 10 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Julie Stockis Breakdown of academic impact, for papers by Massimo Ammirante Breakdown of academic impact, for papers by Veronica C. Ardi Breakdown of academic impact, for papers by Donna Butcher Breakdown of academic impact, for papers by Lopamudra Das Roy Breakdown of academic impact, for papers by Shashank J. Patel Breakdown of academic impact, for papers by Douglas Halverson Breakdown of academic impact, for papers by Sandra Cristea Breakdown of academic impact, for papers by Michal A. Stanczak Breakdown of academic impact, for papers by Ruoyu Ma
Rankless by CCL
2026